Akorn, Inc. has signed a definitive agreement with Azad Pharma to develop and supply Latanoprost, Bimatoprost and Travoprost, three ophthalmic ANDA drug products for the treatment of glaucoma. The products are to be manufactured by Taejoon Pharmaceutical Co. Ltd., located in Seoul, South Korea. Azad served as Taejoon’s agent in this agreement. Taejoon and Azad are responsible for completion of the regulatory dossiers and upon ANDA approval, will manufacture and supply the products to Akorn...